BPC-157 and TB-500 are two distinct research peptides commonly studied in tissue research literature. They have different origins, different structures, and different characterized mechanisms — but they’re often co-studied because of overlapping research interest.
Side-by-Side Comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Length | 15 amino acids | 7 amino acids (fragment) |
| Origin | Fragment of human gastric protective protein | Active fragment of thymosin beta-4 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | LKKTETQ |
| Characterized mechanism | Modulation of NO synthesis, growth factor expression | Actin sequestering, cell migration modulation |
| Stability profile | Unusually stable; survives gastric pH in research models | Standard peptide stability |
Why They’re Often Studied Together
BPC-157 acts on signaling pathways (NO, growth factor expression). TB-500 acts on cytoskeletal dynamics (actin sequestering). Their characterized mechanisms are non-overlapping, which makes them complementary tools in combination tissue research protocols.
The Combination Blend
Matte stocks both as standalone vials (BPC-157 10mg, TB-500 10mg) and as a co-lyophilized BPC-157 / TB-500 Blend 20mg for combination research where a fixed ratio is wanted.
Both compounds ship with per-lot HPLC chromatograms at ≥99% purity. Background reading: Tissue Recovery Peptide Class Research Overview.
Research use only. Not for human consumption. Statements not evaluated by the US FDA.